Abd El-Aty, A.M., Goudah, A., Abo El Sooud, K., 2001. Pharmacokinetics, intramuscular bioavailability and tissue residue profiles of ceftazidime in a rabbit model. Dtsch Tierarztl Wochenschr 108, 168–171.

Acred, P., 1983. Therapeutic and kinetic properties of ceftazidime in animals. Infection 11 Suppl 1, S44-48. https://doi.org/10.1007/BF01641106

Bayer, A.S., Crowell, D.J., Yih, J., Bradley, D.W., Norman, D.C., 1988. Comparative pharmacokinetics and pharmacodynamics of amikacin and ceftazidime in tricuspid and aortic vegetations in experimental Pseudomonas endocarditis. J Infect Dis 158, 355–359. https://doi.org/10.1093/infdis/158.2.355

Bayer, A.S., Norman, D., Kim, K.S., 1985. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 28, 781–785. https://doi.org/10.1128/AAC.28.6.781

McColm, A.A., Ryan, D.M., 1986. Penetration of ceftazidime into the rabbit respiratory tract. J Antimicrob Chemother 18, 593–597. https://doi.org/10.1093/jac/18.5.593

Moody, J.A., Fasching, C.E., Peterson, L.R., Gerding, D.N., 1987. Ceftazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae. Diagn Microbiol Infect Dis 6, 59–67. https://doi.org/10.1016/0732-8893(87)90115-5

Petraitiene, R., Petraitis, V., Kavaliauskas, P., Maung, B.B.W., Khan, F., Naing, E., Aung, T., Zigmantaite, V., Grigaleviciute, R., Kucinskas, A., Stakauskas, R., Georgiades, B.N., Mazur, C.A., Hayden, J.A., Satlin, M.J., Walsh, T.J., 2020. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits. Antimicrob Agents Chemother 64, e02157-19. https://doi.org/10.1128/AAC.02157-19

Sakata, Y., Boccazzi, A., McCracken, G.H., 1983. Pharmacokinetics and bacteriological effect of ceftazidime in experimental Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli meningitis. Antimicrob Agents Chemother 23, 213–217.

Sakata, Y., McCracken, G.H., Thomas, M.L., Olsen, K.D., 1984. Pharmacokinetics and therapeutic efficacy of imipenem, ceftazidime, and ceftriaxone in experimental meningitis due to an ampicillin- and chloramphenicol-resistant strain of Haemophilus influenzae type b. Antimicrob Agents Chemother 25, 29–32. https://doi.org/10.1128/AAC.25.1.29

Shockley, R.K., Fishman, P., Aziz, M., Yannis, R.A., Jay, W.M., 1986. Subconjunctival administration of ceftazidime in pigmented rabbit eyes. Arch Ophthalmol 104, 266–268. https://doi.org/10.1001/archopht.1986.01050140124033

Walstad, R.A., Blika, S., 1985. Penetration of ceftazidime into the normal rabbit and human eye. Scand J Infect Dis Suppl 44, 63–67.

Xiong, Y.Q., Caillon, J., Zhou, X.Y., Potel, G., Bugnon, D., Le Conte, P., Le Gallou, F., Le Floch, R., Baron, D., Drugeon, H., 1995. Treatment of experimental rabbit infective endocarditis due to a multidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and combined with amikacin or sulbactam or both. J Antimicrob Chemother 35, 697–706. https://doi.org/10.1093/jac/35.5.697

Yu, Y.-H., Lin, Y.-T., Hsu, Y.-H., Chou, Y.-C., Ueng, S.W.N., Liu, S.-J., 2021. Biodegradable Antimicrobial Agent/Analgesic/Bone Morphogenetic Protein-Loaded Nanofibrous Fixators for Bone Fracture Repair. Int J Nanomedicine 16, 5357–5370. https://doi.org/10.2147/IJN.S325885

Zhou, J., Xu, P., Chen, H., Yu, Y., Chen, Y., 2005. [Therapeutic effect of ceftazidime in a rabbit model of peritonitis caused by Escherichia coli producing CTX-M-14 extended-spectrum beta-lactamase]. Zhonghua Jie He He Hu Xi Za Zhi 28, 689–693.